Center of Excellence in Higher Education
The First Private University in Bangladesh

Dr. Md. Asaduzzaman Khan

Full Time Faculty
Assistant Professor

PhD in Biochemistry & Molecular Biology, Central South University, China 

MSc in Biochemistry & Molecular Biology, Jahangirnagar University, Bangladesh

Phone: +880-2-55668200 Ext- 6845
Email: asaduzzaman.khan@northsouth.edu
Office: SAC 825 

Curriculum Vitae

 

 

Dr. Md. Asaduzzaman Khan is an assistant Professor at the Department of Biochemistry and Microbiology of North South University, Dhaka, Bangladesh.
Before joining here, he was a Research Scientist in Boston University School of Medicine, Boston, USA. Dr. Khan completed his bachelor and master's in Biochemistry and Molecular Biology from Jahangirnagar University of Bangladesh, and then obtained PhD degree in Biochemistry and Molecular Biology from Central South University of China in 2013. He had then postdoctoral training in Luzhou Medical College and University of Macao. After that, he served as Research Professor at Southwest Medical University of China from 2017 to 2022. Dr. Khan also had contractual short time teaching experiences at Ton-Duc-Thang University of Vietnam, Bangabandhu Sheikh Mujibur Rahman Agricultural University and Brac University of Bangladesh. 
The major research focus of Dr. Khan is molecular biology of cancer, obesity, diabetes and infectious disease. Especially he is interested in small molecules and non-coding RNAs in targeting disease pathways; epithelial to mesenchymal transition and cancer metastasis; DNA methylation and gene regulation etc.  He is an associate member of American Association for Cancer Research (AACR). Dr. Khan was a recipient of research grant from National Science Foundation of China (NSFC) in 2019.  
 
 
 

Selected Peer reviewed papers in journal

  1. Wang Z , Wan X , Khan MA , Peng L , Sun X , Yi X, Chen K (2024). NAT10 promotes liver lipogenesis in mouse through N4-acetylcytidine modification of Srebf1 and Scap mRNA. Lipids in Health and Disease. 23:368 [Q1; IF: 3.9]
  2. Wan X, Wang L, Khan MA, Peng L, Zhang K, Sun X, Yi X, Wang Z, Chen K (2024). Shift work promotes adipogenesis via cortisol-dependent downregulation of EGR3-HDAC6 pathway. Cell Death Discovery. 10: 129. [Q1; IF: 6.1].
  3. Yi X, Wan XX, Khan MA, Sun X, Wang Z, Chen K, Peng L (2024). Expression analysis of circRNAs in human adipogenesis. Diabetes Metabolic Syndrome and Obesity: Targets and Therapy. 17: 45-54. [Q2, IF: 2.8].
  4. Khan MA, Tania M (2023). Cordycepin and kinase inhibition in cancer. Drug Discovery Today. 28(3):103481. [Q1, IF: 6.5].
  5. Sun X, Wan X, Khan MA, Zhang K, Yi X, Wang Z, Chen K (2023). Comprehensive analysis of circRNA expression profiles in Human Brown Adipose Tissue. Diabetes Metabolic Syndrome and Obesity: Targets and Therapy. 16:469-478. [Q2, IF: 2.8].
  6. He YF, Hu XM, Khan MA, Yu BY, Sheng YC, Xiao XZ, Wan XX, Tan SP, Xiong K (2023). HSF1 Alleviates Brain Injury by Inhibiting NLRP3-Induced Pyroptosis in a Sepsis Model. Mediators of Inflammation. 2023:2252255. [Q2, IF: 4.4].
  7. Akter Z, Khan FZ, Khan MA* (2023). Gold nanoparticles in triple-negative breast cancer therapeutics. Current Medicinal Chemistry. 30(3): 316-334. [Q1, IF: 3.5]. 
  8. Khan MA, Zheng M, Fu J, Tania M, Li J, Fu J (2022). Thymoquinone upregulates IL17RD in controlling the growth and metastasis of triple negative breast cancer cells in vitro. BMC Cancer. 22:707. [Q2, IF: 3.4].
  9. Zheng M, Mei Z, Junaid M, Tania M, Fu J, Chen H, Khan MA* (2022). Synergistic role of thymoquinone on anticancer activity of 5-fluorouracil in triple negative breast cancer cells. Anti-Cancer Agents in Medicinal Chemistry. 22(6):1111-1118. [Q3, IF: 2.6].
  10. Wei C, Khan MA (co-1st author), Du J, Cheng J, Tania M, Leung E, Fu J (2022). Cordycepin inhibits triple-negative breast cancer cell migration and invasion by regulating EMT-TFs SLUG, TWIST1, SNAIL1 and ZEB1. Frontiers in Oncology. 12:898583.[Q2, IF: 3.5].
  11. Shariare MH, Khan MA, Al-Masum A, Khan JH, Uddin J, Kazi M (2022). Development of Stable Liposomal Drug Delivery System of Thymoquinone and Its In Vitro Anticancer Studies Using Breast Cancer and Cervical Cancer Cell Lines. Molecules. 27(19):6744. [Q1, IF: 4.2].
  12. Afroz R, Tanvir EM, Tania M, Fu J, Kamal MA, Khan MA* (2022). LPS/TLR4 pathways in breast cancer: insights into cell signaling. Current Medicinal Chemistry. 29(13):2274-2289. [Q1, IF: 3.5].
  13. Wan XX, Zhang DY, Khan MA, Zheng SY, Hu XM, Zhang Q, Yang RH, Xiong K (2022). Stem Cell Transplantation in the Treatment of Type 1 Diabetes Mellitus: From Insulin Replacement to Beta Cells Replacement. Frontiers in Endocrinology. 13: 859638. [Q1, IF: 3.9].
  14. Nyamsambuu A, Khan MA, Zhou X, Chen H (2022). Molecular mechanism of inhibitory effects of melatonin on prostate cancer cell proliferation, migration and invasion. Plos One. 17(1): e0261341. [Q1, IF: 2.7]
  15. Zhang K , Wan X, Khan MA , Sun X, Yi X, Wang Z, Chen K, Peng L (2022). Peripheral Blood circRNA Microarray Profiling Identities hsa_circ_0001831 and hsa_circ_0000867 as Two Novel circRNA Biomarkers for Early Type 2 Diabetic Nephropathy. Diabetes Metabolic Syndrome and Obesity: Targets and Therapy. 15: 2789-2801. [Q2, IF: 2.8].
  16. Babu G, Bin Islam S, Khan MA* (2022). A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh. Molecular Biology Reports. 49: 6725-6739. [Q2, IF: 2.6]
  17. Tania M, Asad A, Li T, Islam MS, Bin Islam S, Hossen MM, Bhuiyan MR, Khan MA* (2021). Thymoquinone against infectious diseases: perspectives in recent pandemics and future therapeutics. Iranian Journal of Basic Medical Sciences. 2021; 24(8): 1014-1022. [Q3, IF: 2.1].
  18. Ali MY, Akter Z, Mei Z, Zheng M, Tania M, Khan MA* (2021). Thymoquinone in autoimmune diseases: therapeutic potential and molecular mechanisms. Biomedicine & Pharmacotherapy. 134: 111157. [Q1, IF: 6.9].
  19. Akter Z, Ahmed FR, Tania M, Khan MA* (2021). Targeting inflammatory mediators: An anticancer mechanism of thymoquinone action. Current Medicinal Chemistry. 28(1): 80-92. [Q1, IF: 3.5].
  20. Junaid M, Akter Y, Afrose SS, Tania M, Khan MA* (2021). Biological role of AKT, and regulation of AKT signaling pathway by thymoquinone: perspectives in cancer therapeutics. Mini-Reviews in Medicinal Chemistry. 21(3): 288-301. [Q2, IF: 3.3].
  21. Afrose SS, Junaid M, Akter Y, Tania M, Zheng M, Khan MA* (2020). Targeting kinases with thymoquinone: a molecular approach to cancer therapeutics. Drug Discovery Today. 25(12): 2294-2306. [Q1, IF: 6.5].
  22. Shawon J, Akter Z, Hossen MM, Akter Y, Sayeed A, Junaid M, Afrose S, Khan MA* (2020). Current landscape of natural products against coronaviruses: perspectives in COVID-19 treatment and antiviral mechanism. Current Pharmaceutical Design. 26(41): 5241-5260. [Q2, IF: 2.6].
  23. Zhang L, Zhou Q, Cheng J, Khan MA, Fu J, Duan C, Sun S, Lv H, Fu J (2020). Targeted next-generation sequencing identified novel compound heterozygous variants in the CDH23 gene causing Usher syndrome type ID in a Chinese patient. Frontiers in Genetics. 11:422. [Q2, IF: 2.8].
  24. Khan MA*, Tania M (2020). Cordycepin in Anticancer Research: Molecular Mechanism of Therapeutic Effects. Current Medicinal Chemistry. 27(6): 983-996. [Q1, IF: 3.5].
  25. Cheng J, Peng J, Fu J, Khan MA, Tan P, Wei C, Deng X, Chen H, Fu J (2020). Identification of a novel germline BRCA2 variant in a Chinese breast cancer family. Journal of Cellular and Molecular Medicine. 24.1676–1683. [Q2, IF: 4.3].
  26. Fu J, Cheng J, Zhou Q, Khan MA, Duan C, Peng J, Lv H, Fu J (2020). Novel compound heterozygous nonsense variants, p.L150* and p.Y3565*, of the USH2A gene in a Chinese pedigree are associated with Usher syndrome type IIA. Molecular Medicine Reports. 3464-3472. [Q2, IF: 3.4]
  27. Khan MA, Tania M, Fu J (2019). Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics. Drug Discovery Today. 24(12):2315-2322. [Q1, IF: 6.5].
  28. Chen Q, Liu J, Zhuang Y, Bai L, Yuan Q, Zheng S, Liao K, Khan MA, Wu Q, Luo C, Liu L, Wang H, Li T (2019). Identification of an IKKβ inhibitor for inhibition of inflammation in vivo and in vitro. Pharmacological Research. 149:104440. [Q1, IF: 9.1].
  29. Agarwal V, Tuli HS, Varol A, Thakral F, Yerer MB, Sak K, Varol M, Jain A, Khan MA, Sethi G (2019). Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements. Biomolecules. 9(11):735. [Q1, IF: 4.8].
  30. Tania M, Shawon J, Saif K, Kiefer R, Safaei Khorram M, Halim MA, Khan MA* (2019). Cordycepin downregulates Cdk-2 to interfere with cell cycle and increases apoptosis by generating ROS in cervical cancer cells: in vitro and in silico study. Current Cancer Drug Targets. 19(2): 152-159. [Q2, IF: 2.3].
  31. Zhou B, Wei C, Khan MA, Chen H, Fu J (2019). Characterization and molecular cloning of novel isoforms of human spermatogenesis associated gene SPATA3. Molecular Biology Reports. 46(4):3827-3834. [Q2, IF: 2.6].
  32. Cheng J, Fu J, Zhou Q, Xiang X, Wei C, Yang L, Khan MA, Lv H, Fu J (2019). A novel splicing variant of the PRPH2 gene in a Chinese family causes autosomal dominant retinitis pigmentosa. Journal of Cellular and Molecular Medicine. 23: 3776–3780. [Q2, IF: 4.3].
  33. Khan MA, Tania M, Fu S, Fu J (2017). Thymoquinone, as an anticancer molecule: from basic research to clinical investigation. Oncotarget. 8(31): 51907-51919. [Q2, IF(2016): 5.168].
  34. Li J, Khan MA (co-1st author), Wei C, Cheng J, Chen H, Yang L, Ijaz I, Fu J (2017). Thymoquinone inhibits the migration and invasive characteristics of cervical cancer cells SiHa and CaSki in vitro by targeting epithelial to mesenchymal transition associated transcription factors Twist1 and Zeb1. Molecules. 22(12): 2105. [Q1, IF: 4.2].
  35. Cheng J, Fu S, Wei C, Tania M, Khan MA, Imani S, Zhou B, Chen H, Xiao X, Wu J, Fu J (2017). Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China. Cancer Biomarkers. 19(1):85-92. [Q2, IF: 2.2].
  36. Wei C, Cheng J, Zhou B, Zhu L, Khan MA, He T, Zhou S, He J, Lu S, Chen H, Zhang D, Zhao Y, Fu J (2016). Tripartite motif containing 28 (TRIM28) promotes breast cancer metastasis by stabilizing TWIST1 protein. Scientific Reports. 6: 29822. [Q1, IF: 3.8].
  37. Khan MA, Tania M, Wei C, Mei Z, Fu S, Cheng J, Xu J, Fu J (2015). Thymoquinone inhibits Cancer metastasis by regulating TWIST1 associated with epithelial to mesenchymal transitions. Oncotarget. 6(23): 19580-19591. [Q2, IF(2016): 5.168].
  38. Tania M, Khan MA (equal contribution), Fu J (2014). Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumor Biology. 35(8): 7335-7342. [Q2, IF(2017):3.650].
  39. Tania M, Khan MA, Xia K (2014). Recent advances in animal model experimentation in autism research. Acta Neuropsychiatrica. 26(5): 264-271. [Q2, IF: 2.6].
  40. Khan MA, Chen HC, Zhang D, Fu J (2013). Twist: A Molecular Target in Cancer Therapeutics. Tumor Biology. 34(5): 2497-2506. [Q2, IF(2017):3.650].
  41. Khan MA, Chen HC, Wan XX, Tania M, Xu A, Chen FZ, Zhang DZ (2013). Regulatory Effects of Resveratrol on Antioxidant Enzymes: A Mechanism of Growth Inhibition and Apoptosis Induction in Cancer Cells. Molecules and Cells. 35(3): 219-225. [Q1, IF: 3.7].
  42. Huang FM, Chen HC, Khan MA, Yang FL, Wan XX, Xu AH, Ou-yang FD, Zhang DZ (2013). CYP2A6, CYP1A1, and CYP2D6 polymorphisms in lung cancer patients from Central South China. Medical Oncology. 30(2): 521. [Q2, IF: 2.8].
  43. Rahman MM, Khan MA* (2013). Anti-cancer potential of South Asian plants. Natural Products and Bioprospecting. 3(3): 74-88. [Q1, IF: 4.8].
  44. Khan MA*, Tania M (2012). Nutritional and Medicinal Importance of Pleurotus mushrooms: An Overview. Food Reviews international. 28(3): 313-329. [Q1, IF: 5.3]
  45. Liu J, Chen HC, Rao ZZ, Khan MA, Wan XX, Xu AH, Zhang N, Zhang D (2011). Identification of heptapeptides interacting with IFN-α-sensitive CML cells. Expert Opinion on Investigational Drugs. 20(12): 1583-1589. [Q1, IF: 4.9].
  46. Chen HC, Chen HJ, Khan MA, Rao ZZ, Wan XX, Tan B, Zhang DZ (2011). Genetic Mutations of p53 and k-ras in Gastric Carcinoma Patients from Hunan, China. Tumor Biology. 32(2): 367-373. [Q2, IF(2017):3.650].
  47. Luo YP, Chen HC, Khan MA, Chen FZ, Wan XX, Tan B, Ou-Yang FD, Zhang DZ (2011). Genetic polymorphisms of metabolic enzymes- CYP1A1, CYP2D6, GSTM1 and GSTT1, and gastric carcinoma Tumor Biology. 32(1): 215-222. [Q2, IF(2017): 3.650].
  48. Moonmoon M, shelly NJ, Khan MA*, Uddin MN, Hossain K, Tania M, Ahmed S (2011). Effects of different levels of wheat bran, rice bran and maize powder supplementation with saw dust on the production of shiitake mushroom (Lentinus edodes (Berk.) Singer). Saudi Journal of Biological Sciences. 18(4): 323-328. [Q1, IF(2022): 4.4]
  49. Tania M, Khan MA, Zhang H, Li J, Song Y (2010). Autotaxin: a protein with two faces. Biochemical and Biophysical Research Communications. 401(4): 493-497. [Q1, IF: 2.5].
  50. Tania M, Khan MA, Song Y (2010). Association of Lipid Metabolism with Ovarian Cancer. Current Oncology. 17(5): 6-11. [Q2, IF: 2.8].
  51. Khan MA, Tania M, Zhang DZ, Chen HC (2010). Antioxidant Enzymes and Cancer. Chinese Journal of Cancer Research. 22(2): 87-92. [Q2, IF: 7.0].

 

Selected conference Papers

  1. Khan MA, Zheng M, Fu J (2019). Epigenetic modification of oncogenes or tumor suppressor genes by thymoquinone in triple negative breast cancer. Proceedings of Annual meeting of American Association of Cancer Research; March 29- April 04, at Atlanta, GA, USA (Abstract No. 3834). Published in CANCER RESEARCH 2019; 79 (13suppl): 3834.
  2. Khan MA, Tania M, Wei C, Fu J (2015). Relationship between transcription factor TWIST1 and microRNA34a in metastatic cancer cells. Proceedings of Annual meeting of American Association of Cancer Research; April 18-22, 2015 at Philadelphia, PA, USA (Abstract No. 1978). Published in CANCER RESEARCH 2015; 75 (15suppl): 1978.

 

Selected Book chapters

  1. Junaid M, Akter Y, Afrose SS, Tania M, Khan MA* (2020). Apoptotic cell death: important cellular process as chemotherapeutic target (chapter 4). In: Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models (Editor: Tuli HS). Springer. PP: 65-88. ISBN: 978-981-15-7585-3/ 978-981-15-7586-0.
  2. Zhou J, Chen S, Khan MA, Xiao T, Tania M, Khan MS, Fu J (2020). Epigenetics in Triple-Negative Breast Cancer (chapter 4). In: Triple-negative Breast Cancer (Editor: Deng X, Tang F, Rosol TJ). World Scientific. PP: 71-105. ISBN: 978-981-3277-75-5/ 978-981-3277077-9.

PhD in Biochemistry & Molecular Biology [2013; Central South University, China]

MSc in Biochemistry & Molecular Biology [2005; Jahangirnagar University, Bangladesh]

BSc in Biochemistry & Molecular Biology [2004; Jahangirnagar University, Bangladesh]

Assistant Professor, Biochemistry & Microbiology, North South University, Dhaka, Bangladesh (2024/01~)

Research Scientist, Boston University School of Medicine, Boston, MA, USA (2023/07-2023/12)

Assistant Professor (Adjunct), Microbiology Program, Brac University, Dhaka, Bangladesh (2023/01-2023/05)

Research Professor, Southwest Medical University, Luzhou, Sichuan, China (2017-2022)

Lecturer & Researcher, Ton Duc Thang University, Ho chi Minh city, Vietnam (2016/10- 2016/12)

Postdoctoral Fellow, University of Macau, Macau SAR (China) (2015-2016)

Postdoctoral Fellow, Luzhou Medical College (Zhejiang University), Luzhou, China (2013- 2015)

Visiting Teacher, Changsha Medical College, Hunan, China (2010-2011)

Visiting Teacher, BSMR Agricultural University, Bangladesh (2008-2009)

Research Fellow, National Mushroom Dev. & Ex. Center, Bangladesh (2005-2009)

BBT314- Protein & Enzyme Chemistry
BBT315- Metabolism
BBT221- Human Physiology 
BIO201- Introduction to Biochemistry & Biotechnology
BIO103- Biology I
CHE101- General Chemistry
BIO201L- Introduction to Biochemistry & Biotechnology Lab
CHE101L- General Chemistry Lab
BIO103L- Biology I Lab

American Association for Cancer Research (AACR)

Nature Study Society of Bangladesh (NSSB)

Global Network of Bangladeshi Biotechnologists (GNOBB)

Molecular biology of cancer, obesity and lung disease

Epigenetics

miRNA

circRNA

Small molecules

Nutraceuticals

Human genetics